A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke
NEJM 382:9-19,81, Amarenco, P.,et al, 2020
Cholesterol Lowering and Prevention of Stroke
Stroke 50:537-541, Hackam, D.G. & Hegele, R.A., 2019
Secondary Prevention after Ischemic Stroke or Transient Ischemic Attack
NEJM 366:1914-1922;, Davis, S.M. & Donnan, G.A., 2012
The "Million Hearts" Initiative - Preventing Heart Attacks and Strokes
NEJM 365:e27, Frieden, T.R.,et al, 2011
Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial by Stroke Subtypes
Stroke 40:1405-1409, Amarenco,P.,et al, 2009
Interventions in the Management of Serum Lipids for Preventing Stroke Recurrence
Stroke 40:e622-e623, Manktelow,B. &Potter,J., 2009
Statin Treatment and the Occurrence of Hemorrhagic Stroke in Patients With a History of Cerebrovascular Disease
Stroke 39:497-502, Vergouwen,M.D.I.,et al, 2008
Relative Effects of Statin Therapy on Stroke and Cardiovascular Events in Men and Women: Secondary Analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study
Stroke 39:2444-2448, Goldstein,L.B.,et al., 2008
Expanding Indications for Statins in Cerebral Ischemia
Arch Neurol 62:67-72,23, Ovbiagele,B.,et al, 2005
Efficacy and Safety of Cholesterol-Lowering Treatment: Prospective Meta-Analysis of Data from 90056 Participants in 14 Randomised Trials of Statins
Lancet 366:1267-1278, Cholesterol Treatment Trialists (CTT) Collaborators, 2005
High-Density Lipoprotein Cholesterol and Ischemic Stroke in the Elderly
JAMA 285:2729-2735, Sacco,R.L.,et al, 2001
Statins for Stroke Prevention?
Lancet 357:1548-1549, Sandercock,P., 2001
HMG-CoA Reductase Inhibitors (Statins)
Neurol 54:790-795, Hess,D.C.,et al, 2000
Pravastatin Therapy and The Risk of Stroke
NEJM 343:317-326, White,H.D. et al, 2000
Prevention of a First Stroke,A Review of Guidelines and a Multidisciplinary Consensus Statement from the National Stroke Association
JAMA 281:1112-1120,1146, Gorelick,P.B.,et al, 1999
Is Cholesterol a Risk Factor for Stroke? No
Arch Neurol 56:1521-1524, Landau,W.M., 1999
Is Cholesterol a Risk Factor for Stroke? Yes
Arch Neurol 56:1518-1520,1524, Demchuk,A.M.,et al, 1999
Effect of HMGcoA Reductase Inhibitors on Stroke, A Meta-Analysis of Controlled Trials
Ann Int Med 128:89-95, Bucher,H.C.,et al, 1998
Influence of Cholesterol on Survival After Stroke:Retrospective Study
BMJ 314:1584-1588, Dyker,A.G.,et al, 1997
A Randomized, Double-Blind, Placebo Controlled Trial of Simvastatin to Treat Alzheimer Disease
Neurol 77:556-563, Sano, M.,et al, 2011
Effect of Rosuvastatin on Progression of Carotid Intima-Media Thickness in Low-Risk Individuals with Subclinical Atherosclerosis
JAMA 297:1344-1353,1376, Crouse III,J.R.,et al, 2007
Statin Use and the Risk of Incident Dementia
Arch Neurol 62:1047-1051, Rea,T.D.,et al, 2005
Lipid-Lowering Agent Use at Ischemic Stroke Onset is Associated with Decreased Mortality
Neurol 65:253-258, Elkind,M.S.V.,et al, 2005
Lipid Lowering Agents Are Associated With a Slower Cognitive Decline in Alzheimers Disease
JNNP 76:1624-1629, Masse,I.,et al, 2005
Pravastatin Reduces Carotid Intima-Media Thickness Prog in an Asympt Hypercholesterolemic Pop, CAIUS Study
Am J Med 101:627-634, Mercuri,M.,et al, 1996
Toxic and Drug-Induced Myopathies
JNNP 80:832-838, Dalakas,M.C., 2009
Statin Treatment and Stroke Outcome in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial
Stroke 40:3526-3531,3413, Goldstein,L.,et al, 2009
Hemorrhagic Stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels Study
Neurol 70:2364-2370,2355, Goldstein,L.B.,et al, 2008
Atorvastatin for the Treatment of Mild to Moderate Alzheimer Disease
Arch Neurol 62:753-757, Sparks,D.L.,et al, 2005
Incidence of Hospitalized Rhabdomyloysis in Patients Treated With Lipid-Lowering Drugs
JAMA 292:2585-2590, Graham,D.J.,et al, 2004
Cholesterol and the Risk of Ischemic Stroke
Stroke 34:2930-2934, Bowman,T.S.,et al, 2003
Safety of HMG-CoA Reductase Inhibitors: Focus on Atorvastatin
Cardiovasc Drugs Ther 15:211-218, Bernini,F.,et al, 2001
Cholesterol and Strokes
BMJ 320:459-460, Oliver,M.F., 2000
Treating Nondementia Illnesses in Patients With Dementia
JAMA 283:3230-3235, Brauner,D.J. et al, 2000
Vascular Effects of Statins in Stroke
Stroke 28:2315-2320, Delanty,N.&Vaughan,C.J., 1997
Reduction in Carotid Arterial Wall Thickness Using Lovastatin & Dietary Therapy
Ann Int Med 124:548-556, Hodis,H.N.,et al, 1996
Parkinsonism Unmasked by Lovastatin
Ann Neurol 37:685-686, Muller,T.,et al, 1995
HMG-CoA Reductase Inhibitor Therapy and Peripheral Neuropathy
Ann Int Med 120:970, Jacobs,M.B., 1994
One-Year Reduction and Longitudinal Analysis of Carotid Intima-Media Thickness Associated with Colestipol/Niacin Therapy
Stroke 24:1779-1783, Mack,W.J.,et al, 1993
Cholesterol-Lowering Agent Myopathy (CLAM)
Neurol 41:1159-1160, London,S.F.,et al, 1991
Myopathy and Rhabdomyolysis Associated with Lovastatin-Gemfibrozil Combination Therapy
JAMA 264:71-75, Pierce,L.R.,et al, 1990
Clofibrate-Induced Muscle Damage with Myoglobinuria & Cardiomyopathy
NEJM 296:942, Smals,A.G.H., 1977
Platelet-Inhibiting Drugs in the Prevention of Clinical Thrombotic Disease
NEJM 293:174, Genton,E.,et al, 1975
The Treatment of Cerebrovascular Disease with Clofibrate
VA Cooperative Study Group, Stroke 4:6841973., , 1973
Clofibrate for the Treatment of Occlusive CVD-Correspondence
NEJM 287:671, Hirsch,S.,et al, 1972